Arbutus Biopharma Announces Preliminary Results of $230M Tender Offer

Key Facts

1Arbutus Biopharma announced preliminary results for its modified Dutch auction tender offer to repurchase up to $230 million of its common shares.

Arbutus Biopharma announced preliminary results for its modified Dutch auction tender offer to repurchase up to $230 million of its common shares. The company said in a statement via GlobeNewswire that it expects to take up and pay for 46 million shares at a price of $5.00 per share, which was the lower end of the initial tender range of $5.00 to $5.75 per share.

The company is utilizing the mechanism to return capital to shareholders and cancel the repurchased shares to potentially increase the value of remaining equity. ABUS closed at $4.69 on September 29, 2026, trading below the preliminary purchase price set in the offer.